Back to News
Market Impact: 0.35
AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial
Source: Nasdaq
Healthcare & Biotech
AstraZeneca reported that full Phase 3 CROSSING trial results showed Tezspire improved disease remission and swallowing symptoms in adolescents and adults with eosinophilic esophagitis. The report provided no numerical effect sizes or additional trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
AZN0.75
More News
- TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
- Jefferies puts AstraZeneca kidney drug trial success odds at 59%
- TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
- AstraZeneca and Oracle team up on AI to find patients for drug trials
- Oracle stock rises nearly 2% today: here's why
- A top medical technology stock is trading at a big discount. Here's why I'm buying
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Tools for Pension Funds and Allocators
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals